275 related articles for article (PubMed ID: 17549478)
61. Charcot-Leyden crystals in the trephine biopsy of a patient with a FIP1L1-PDGFRA - positive myeloproliferative disorder.
Lyall H; O'Connor S; Clark D
Br J Haematol; 2007 Aug; 138(4):405. PubMed ID: 17593250
[No Abstract] [Full Text] [Related]
62. Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib.
Burbury K; Chew LP; Westerman D; Catalano A; Seymour JF
Leuk Lymphoma; 2011 Feb; 52(2):335-8. PubMed ID: 21281241
[No Abstract] [Full Text] [Related]
63. Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
[TBL] [Abstract][Full Text] [Related]
64. Imatinib-responsive hypereosinophilic syndrome.
Robyn J
Leuk Res; 2006 Aug; 30(8):915-6. PubMed ID: 16530830
[No Abstract] [Full Text] [Related]
65. [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia].
Leeksma OC; de Ruiter GS; van der Hulst VP; Terpstra WE; Cools J; Vandenberghe P
Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1936-43. PubMed ID: 16999279
[TBL] [Abstract][Full Text] [Related]
66. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
Cools J; Stover EH; Boulton CL; Gotlib J; Legare RD; Amaral SM; Curley DP; Duclos N; Rowan R; Kutok JL; Lee BH; Williams IR; Coutre SE; Stone RM; DeAngelo DJ; Marynen P; Manley PW; Meyer T; Fabbro D; Neuberg D; Weisberg E; Griffin JD; Gilliland DG
Cancer Cell; 2003 May; 3(5):459-69. PubMed ID: 12781364
[TBL] [Abstract][Full Text] [Related]
67. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
Yamada Y; Cancelas JA; Rothenberg ME
Int Arch Allergy Immunol; 2009; 149 Suppl 1():102-7. PubMed ID: 19494514
[TBL] [Abstract][Full Text] [Related]
68. The results of imatinib therapy for patients with primary eosinophilic disorders.
Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J
Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506
[No Abstract] [Full Text] [Related]
69. [Sustained hematologic response in chronic eosinophilic leukemia with low dose imatinib. Report of one case].
Torres C D; Chandía M
Rev Med Chil; 2014 Apr; 142(4):516-20. PubMed ID: 25117044
[TBL] [Abstract][Full Text] [Related]
70. Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response?
Pitini V; Arrigo C; Altavilla G; Naro C; Righi M
Leuk Res; 2007 May; 31(5):725-6. PubMed ID: 16978696
[No Abstract] [Full Text] [Related]
71. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
Pardanani A; Tefferi A
Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
[TBL] [Abstract][Full Text] [Related]
72. Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome.
Rotoli B; Catalano L; Galderisi M; Luciano L; Pollio G; Guerriero A; D'Errico A; Mecucci C; La Starza R; Frigeri F; Di Francia R; Pinto A
Leuk Lymphoma; 2004 Dec; 45(12):2503-7. PubMed ID: 15621768
[TBL] [Abstract][Full Text] [Related]
73. [Endomyocardial fibrosis in chronic eosinophilic leukemia].
Winter L; Zellweger MJ; Bremerich J
Rofo; 2009 Jul; 181(7):691-3. PubMed ID: 19401974
[No Abstract] [Full Text] [Related]
74. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.
Stone RM; Gilliland DG; Klion AD
Semin Oncol; 2004 Apr; 31(2 Suppl 6):12-7. PubMed ID: 15175999
[TBL] [Abstract][Full Text] [Related]
75. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.
Score J; Curtis C; Waghorn K; Stalder M; Jotterand M; Grand FH; Cross NC
Leukemia; 2006 May; 20(5):827-32. PubMed ID: 16498388
[TBL] [Abstract][Full Text] [Related]
76. Successful treatment of ulcerative colitis associated with hypereosinophilic syndrome/chronic eosinophilic leukemia.
Awano N; Ryu T; Yoshimura N; Takazoe M; Kitamura S; Tanaka M
Intern Med; 2011; 50(16):1741-5. PubMed ID: 21841337
[TBL] [Abstract][Full Text] [Related]
77. Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment.
Selvi N; Kaymaz BT; Sahin HH; Pehlivan M; Aktan C; Dalmızrak A; Inalpolat E; Kosova B; Yılmaz M; Okan V; Saydam G
Mol Biol Rep; 2013 Feb; 40(2):1591-7. PubMed ID: 23076533
[TBL] [Abstract][Full Text] [Related]
78. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Pan J; Quintás-Cardama A; Manshouri T; Giles FJ; Lamb P; Tefferi A; Cortes J; Kantarjian H; Verstovsek S
Leukemia; 2007 Jul; 21(7):1395-404. PubMed ID: 17495975
[TBL] [Abstract][Full Text] [Related]
79. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
Ogbogu PU; Bochner BS; Butterfield JH; Gleich GJ; Huss-Marp J; Kahn JE; Leiferman KM; Nutman TB; Pfab F; Ring J; Rothenberg ME; Roufosse F; Sajous MH; Sheikh J; Simon D; Simon HU; Stein ML; Wardlaw A; Weller PF; Klion AD
J Allergy Clin Immunol; 2009 Dec; 124(6):1319-25.e3. PubMed ID: 19910029
[TBL] [Abstract][Full Text] [Related]
80. Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia.
Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Seferyńska I; Raźny M; Rodzaj M; Żuk E; Kyrcz-Krzemień S
Cancer Chemother Pharmacol; 2011 Apr; 67(4):967-9. PubMed ID: 21327932
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
